Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
详细信息 查看全文
- 作者：Ronald P. Taylor ; rpt@virginia.edu" class="auth_mail" title="E-mail the corresponding author ; Margaret A. Lindorfer
- 关键词：ADCC ; antibody-de-pendent cytotoxicity ; ALM ; alemtuzumab ; CLL ; chronic lymphocytic leukemia ; CCP ; complement control protein ; CDC ; complement-dependent cytotoxicity ; MAC ; membrane attack complex ; NIP ; 5-iodo-4-hydroxy-3-nitrophenacetyl ; OFA ; ofatumumab ; rILYd4 ; recombinant form of domain 4 of bacterial toxin intermedilysin ; RTX ; rituximab
- 刊名：Seminars in Immunology
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：28
- 期：3
- 页码：309-316
- 全文大小：963 K
文摘
- •
Complement is activated in vivo when CD20 mAbs RTX or OFA are infused in CLL patients.
- •
The detailed cellular events that occur in vitro during mAb-mediated CDC have been elucidated for CD20 mAbs.
- •
New and innovative approaches should allow for development of far more effective complement-fixing mAbs for cancer immunotherapy.